Sergi Ferré

Active 1990–2026

136
Papers
20,734
Citations
90
h-index
133
i10-index

Citations

Citations per year for Sergi Ferré1990: 1 citations1991: 11 citations1992: 13 citations1993: 20 citations1994: 24 citations1995: 26 citations1996: 52 citations1997: 56 citations1998: 60 citations1999: 83 citations2000: 80 citations2001: 96 citations2002: 65 citations2003: 140 citations2004: 141 citations2005: 148 citations2006: 176 citations2007: 327 citations2008: 271 citations2009: 309 citations2010: 383 citations2011: 249 citations2012: 155 citations2013: 228 citations2014: 241 citations2015: 205 citations2016: 166 citations2017: 124 citations2018: 226 citations2019: 605 citations2020: 451 citations2021: 489 citations2022: 479 citations2023: 250 citations2024: 340 citations2025: 123 citations2026: 15 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,192 citing papers, 26.2% of this breakdownItaly: 358 citing papers, 7.9% of this breakdownSpain: 340 citing papers, 7.5% of this breakdownUnited Kingdom: 275 citing papers, 6% of this breakdownGermany: 243 citing papers, 5.3% of this breakdownChina: 212 citing papers, 4.7% of this breakdownSweden: 208 citing papers, 4.6% of this breakdownFrance: 193 citing papers, 4.2% of this breakdownCanada: 164 citing papers, 3.6% of this breakdownJapan: 119 citing papers, 2.6% of this breakdownPortugal: 110 citing papers, 2.4% of this breakdownAustralia: 104 citing papers, 2.3% of this breakdown
0%26.2%Other 22.7%

Fields

  • Biochemistry, Genetics and Molecular Biology39.5%
  • Medicine26.4%
  • Neuroscience25.7%
  • Psychology3.5%
  • Immunology and Microbiology1.9%
  • Chemistry0.7%
  • Other2.3%

Topics

  • Receptor Mechanisms and Signaling11.1%
  • Adenosine and Purinergic Signaling7%
  • Neuroscience and Neuropharmacology Research6.9%
  • Neurotransmitter Receptor Influence on Behavior5.8%
  • Neuropeptides and Animal Physiology4%
  • Parkinson's Disease Mechanisms and Treatments2.9%
  • Other62.3%

Coauthors

All papers

Open in search
  1. The Management of Restless Legs Syndrome: An Updated Algorithm

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Mayo Clinic Proceedings 2021 cited by 186

  2. Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1–A2AReceptor Heteromers

    Authors: , , , , , , , , , , , , , , , , , - Journal of Neuroscience 2006 cited by 589

  3. Evidence That Sleep Deprivation Downregulates Dopamine D2R in Ventral Striatum in the Human Brain

    Authors: , , , , , , , , , - Journal of Neuroscience 2012 cited by 251

  4. G Protein–Coupled Receptor Oligomerization Revisited: Functional and Pharmacological Perspectives

    Authors: , , , , , , , , - Pharmacological Reviews 2014 cited by 557

  5. Brain-iron deficiency models of restless legs syndrome

    Authors: , , - Experimental Neurology 2022 cited by 55

  6. New Insights into the Neurobiology of Restless Legs Syndrome

    Authors: , , , - The Neuroscientist 2018 cited by 147

  7. G protein-coupled receptor-effector macromolecular membrane assemblies (GEMMAs)

    Authors: , , , , , , , - Pharmacology & Therapeutics 2021 cited by 61

  8. An update on the mechanisms of the psychostimulant effects of caffeine

    Authors: - Journal of Neurochemistry 2007 cited by 442

  9. Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain

    Authors: , , , , , , , , , - Translational Psychiatry 2015 cited by 161

  10. Control of glutamate release by complexes of adenosine and cannabinoid receptors

    Authors: , , , , , , , , , , , , , , , - BMC Biology 2020 cited by 87

  11. Adenosine–dopamine receptor–receptor interactions as an integrative mechanism in the basal ganglia

    Authors: , , , , - Trends in Neurosciences 1997 cited by 822

  12. Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids

    Authors: , , , , , , , , , , , , , , , , - Neuropsychopharmacology 2007 cited by 250

  13. Mechanisms of the psychostimulant effects of caffeine: implications for substance use disorders

    Authors: - Psychopharmacology 2016 cited by 204

  14. Evidence for functional pre-coupled complexes of receptor heteromers and adenylyl cyclase

    Authors: , , , , , , , , , , , - Nature Communications 2018 cited by 126

  15. Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum

    Authors: , , , - Neuropharmacology 2022 cited by 48

  16. Building a new conceptual framework for receptor heteromers

    Authors: , , , , , , , , , , , , , , , , , - Nature Chemical Biology 2009 cited by 392

  17. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum

    Authors: , , , - Journal of Neurochemistry 2005 cited by 172

  18. Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.

    Authors: , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 1991 cited by 550

  19. Adenosine A2A receptors and basal ganglia physiology

    Authors: , , , , - Progress in Neurobiology 2007 cited by 390

  20. Sleep Deprivation Decreases Binding of [11C]Raclopride to Dopamine D2/D3Receptors in the Human Brain

    Authors: , , , , , , , , , , , - Journal of Neuroscience 2008 cited by 190

  21. Psychostimulant pharmacological profile of paraxanthine, the main metabolite of caffeine in humans

    Authors: , , , , , , , , , , , - Neuropharmacology 2012 cited by 89

  22. Evidence for Noncanonical Neurotransmitter Activation: Norepinephrine as a Dopamine D2-Like Receptor Agonist

    Authors: , , , , , , - Molecular Pharmacology 2016 cited by 85

  23. Opioid–galanin receptor heteromers mediate the dopaminergic effects of opioids

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 cited by 67

  24. Preferential Gs protein coupling of the galanin Gal1 receptor in the µ-opioid-Gal1 receptor heterotetramer

    Authors: , , , , , , , , , , , , , , , - Pharmacological Research 2022 cited by 35